by
Gus Iversen, Editor in Chief | November 21, 2025
GE HealthCare has announced plans to acquire Intelerad in a $2.3 billion cash transaction aimed at broadening the company’s cloud-enabled imaging portfolio across care settings.
The acquisition, expected to close in the first half of 2026 pending regulatory approval, will bring Intelerad’s enterprise imaging solutions, including cloud PACS, AI-enabled workflow orchestration, and image sharing, under GE HealthCare’s umbrella. Intelerad’s platform is widely used across outpatient, ambulatory, and teleradiology settings, and is designed for both radiology and cardiology.
According to GE HealthCare, the deal will support its ongoing transition toward a software-as-a-service (SaaS) model and help accelerate its goal to triple its cloud-enabled offerings by 2028. The Chicago-based company also anticipates the acquisition will significantly boost recurring revenue and expand its footprint into a segment it estimates to be worth more than $2 billion globally.
Ad Statistics
Times Displayed: 357
Times Visited: 1 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
“As hospital and ambulatory care providers face increased demand for imaging and rising patient volumes, they are looking to simplify and unify their workflows,” said Peter Arduini, president and CEO of GE HealthCare. “Our acquisition of Intelerad will bring additional cloud-enabled and intelligent solutions in radiology and cardiology into our portfolio of products.”
Intelerad, founded in Montreal in 1999, serves more than 1,500 healthcare organizations globally and has grown to become a key provider of imaging software in outpatient and enterprise settings. The company’s software is known for its scalability and integration across imaging subspecialties.
GE HealthCare projects Intelerad will generate approximately $270 million in revenue in its first full year under GE, with roughly 90% of that revenue recurring. The company expects the acquisition to be accretive to revenue and adjusted EBIT margin at close, though slightly dilutive to adjusted earnings per share in the near term due to financing costs.
Evercore advised GE HealthCare on the deal, while UBS Investment Bank advised Intelerad.
